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Abstract
Chronic pelvic pain (CPP) affects 2.1–24% of women. Frequently, no underlying pathology
is identified, and the pain is difficult to manage. Gabapentin is prescribed for CPP despite
no robust evidence of efficacy. We performed a pilot trial in two UK centres to inform the
planning of a future multicentre RCT to evaluate gabapentin in CPP management. Our pri-
mary objective was to determine levels of participant recruitment and retention. Secondary
objectives included estimating potential effectiveness, acceptability to participants of trial
methodology, and cost-effectiveness of gabapentin. Women with CPP and no obvious pel-
vic pathology were assigned to an increasing regimen of gabapentin (300-2700mg daily) or
placebo. We calculated the proportion of eligible women randomised, and of randomised
participants who were followed up to six months. The analyses by treatment group were by
intention-to-treat. Interviews were conducted to evaluate women’s experiences of the trial.
A probabilistic decision analytical model was used to estimate cost-effectiveness. Between
September 2012–2013, 47 women (34% of those eligible) were randomised (22 to gaba-
pentin, 25 to placebo), and 25 (53%) completed six-month follow-up. Participants on gaba-
pentin had less pain (BPI difference 1.72 points, 95% CI:0.07–3.36), and an improvement in
mood (HADS difference 4.35 points, 95% CI:1.97–6.73) at six months than those allocated
placebo. The majority of participants described their trial experience favorably. At the UK
threshold for willingness-to-pay, the probabilities of gabapentin or no treatment being cost-
effective are similar. A pilot trial assessing gabapentin for CPP was feasible, but uncertainty
remains, highlighting the need for a large definitive trial.
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The prevalence of chronic pelvic pain (CPP) ranges from 2.1% to 24% of the female population
worldwide [1]. It is the reason for 20% of gynaecological consultations and causes a 45% reduc-
tion in work productivity [2]. The pathogenesis of the painful symptoms experienced by
women with CPP is poorly understood. They can be associated with specific pathological pro-
cesses, such as endometriosis, but up to 55% of women with CPP appear to have no obvious
underlying pathology [3]. The management of CPP is difficult [4] because in the absence of
underlying pathology, no established gynaecological treatments are available.
Gabapentin (a GABA analogue) is being increasingly prescribed in family medicine for
CPP. With the support of the Scottish Primary Care Research Network, we surveyed a random
group of Scottish family medicine practitioners to determine prescribing practice of gabapentin
for CPP in women. Of the family medicine practitioners who responded to our survey, over
74% said that they would consider it as a treatment option for this condition. It is also recom-
mended by some physicians for CPP in a multi-disciplinary setting, despite no evidence on
which to base this recommendation, and no clear mechanism of action.
The efficacy of gabapentin has been documented for other chronic pain conditions: painful
diabetic neuropathy, post-herpetic neuralgia, mixed neuropathic pain conditions, spinal cord
injury and phantom limb pain [5]. In some of these trials, gabapentin has also been shown to
improve sleep, mood and other elements of quality of life. To our knowledge, only one study
has evaluated the use of gabapentin for CPP. This study (56 patients) compared gabapentin
against amitriptyline for treatment of CPP and showed that gabapentin had greater efficacy
(80% compared to 70% improvement in pain scores at 12 months) [6]. However, the signifi-
cance of the effect on quality of life provided by gabapentin in the management of CPP was not
evaluated and the study population included women with endometriosis and vulval conditions.
Ideally, a definitive evaluation of the efficacy of gabapentin in the management of CPP in
women with no obvious underlying pathology requires a large carefully designed multicentre
randomized controlled trial with appropriate inclusion and exclusion criteria. This was a pilot
study to assess the processes that are vital to the success of such a trial.
Materials and Methods
Study protocol
The study protocol was published online prior to participant recruitment [7].
Ethical approval
The study received ethical approval from the Scotland A Research Ethics Committee (REC 12/
SS/0005) on 26 January 2012. All patients gave written informed consent.
Participants
Women were recruited from gynaecology outpatient clinics, gynaecology wards and day sur-
gery units between 10 September 2012 and 30 September 2013 (follow-up of last participant in
completed 31 March 2014). They were eligible if they were aged between 18 and 50 years, had
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suffered from pelvic pain that was located within the true pelvis or between and below anterior
iliac crests for greater than six months [8], had associated functional disability, had no obvious
pelvic pathology at laparoscopy (between six months and two weeks prior to randomization)
and were using effective contraception. They were excluded if they had known pelvic pathology
such as endometriosis or an ovarian cyst, were already taking gabapentin or pregabalin, were
due to undergo surgery in the next six months, had a history of significant renal impairment,
were allergic to gabapentin, were breast feeding or were pregnant or planning pregnancy in the
next six months.
Sample size
We used a confidence interval approach to estimate the sample size required to estimate the
proportion lost to follow up. We wished to show that the loss to follow-up was<20%. A 95%
CI for 20% of 60 participants (12/60) is 11%–32%. We estimated that we would recruit approx-
imately 3–4 participants per month from each centre and we aimed to recruit 60 participants
over a nine-month recruitment period. However, due to staffing issues and consequent slow
recruitment this period was extended to 12 months.
Study design
This was a two-arm prospective parallel group 1:1 randomized controlled pilot trial, in two
centres in Scotland, UK (NHS Lothian and NHS Grampian). Participants, all clinical staff, and
those recording outcomes were blind to the allocated treatment until all outcome data had
been recorded. After this point, individual participants were unblinded to their allocated treat-
ment. The study team was not unblinded until after the database was finalized and locked.
Interventions
After consent was obtained, eligible women were randomized by the clinical research team to
either gabapentin or an identical-looking placebo using a web-based system that ensured allo-
cation concealment. We used randomized blocks of size four, and stratified by centre. Partici-
pants were started on 300 mg gabapentin daily (or equivalent in placebo tablets) and increased
in 300 mg increments each week until they reported a 50% pain reduction or side effects, up to
a maximum dose of 2700 mg (or equivalent in placebo tablets). Participants were advised to
continue with their allocated treatment for six months.
Primary and secondary objectives
The primary objective was to determine whether it is possible to achieve acceptable levels of
recruitment and retention in two UK centres. The secondary objectives were to estimate the
effectiveness of gabapentin; the acceptability to participants of the proposed methods of
recruitment, randomization, drug treatments and assessment tools; and to determine whether
gabapentin is likely to be cost-effective given the current level of uncertainty and to ascertain
whether it is appropriate to conduct further research to evaluate the potential value of
gabapentin.
Outcome measures
The clinical research team kept an electronic log of women who fulfilled the eligibility criteria,
women who were invited to participate in the study, women recruited and women who left the
trial early. Reasons for non-recruitment (e.g. non-eligibility, refusal to participate, administra-
tive error), reasons for withdrawal and loss to follow-up were also recorded. A questionnaire
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was given to all participants at randomization (0 months) and at 3 months. This included a
Visual Analogue Scale (VAS), Brief Pain Inventory (BPI), Pain Disability Questionnaire
(PDQ), Hospital Anxiety and Depression Score (HADS), EQ5D Quality of Life (QoL), WHO
QoL, Measure Yourself Medical Outcome Profile (MYMOP) and demographics. A further
questionnaire was given to all participants at 6 months, which included the above and addi-
tional questions on whether they believed that they were receiving gabapentin or placebo and
questions on acceptability of the allocated medication/treatment regimes (and compliance)
and on the acceptability of the above data collection methods.
Statistical analysis
A Statistical Analysis Plan was agreed prior to database lock. We calculated the proportion of
eligible women randomized and of randomized participants who were followed up to six
months, and provided estimates of these, with 95% confidence intervals. In addition, we deter-
mined the nature and number of unanswered questions in each questionnaire. The analyses by
treatment group in this report are by intention-to-treat (ITT), in which all participants who
were randomized into the study were analyzed in the group to which they were randomized,
regardless of treatment received. A per protocol analysis was run in which participants who
received less than two weeks of trial medication were removed. No participants received the
opposite treatment to that allocated. The per protocol analysis removed three participants
from the gabapentin arm, and eight from the placebo arm, but the results were very similar to
those from the ITT analysis, and are therefore not presented here. For each outcome measure,
the difference between treatment groups was calculated using analysis of covariance, adjusting
for baseline scores. The EQ5D subscales were analyzed as changed versus not changed using
Fisher’s Exact test, due to the small number of participants in some of the categories. Where
there were missing data for an outcome variable, those records were removed from the analysis
for that variable. Statistical analyses were performed using SAS software version 9.3 (SAS Insti-
tute, Cary NC, USA). There were no interim analyses. There was an eight-month extension to
the funding, due to a late start date and slow recruitment. The study then continued until the
planned date of finishing recruitment.
Qualitative analysis
We had planned to invite women to participate in focus group discussions of the trial experi-
ence six months into the trial. However, this was not practically possible due to insufficient par-
ticipant numbers (could not reach optimum size for a focus group i.e. six to eight participants).
Instead, we offered individual semi-structured telephone interviews before unblinding that
were recorded on a structured coding sheet. The interviews were analyzed thematically to iden-
tify the issues of importance to participants not covered in the questionnaires, their feelings
about trial participation and experiences with prescribed medication.
Health economic analysis
A probabilistic decision analytical model was used to estimate the potential cost-effectiveness
of gabapentin compared with no active treatment, from the perspective of the NHS and per-
sonal social services (PSS). A decision tree model replicated the potential consequences of
patients within the trial. Data relating to health outcomes (in terms of quality adjusted life
years), healthcare resource use and direct medical costs were estimated from the results of the
existing pilot study. The estimation of total costs took into account the costs of trial medication
and GP contacts; quality adjusted life years associated were calculated based on the change
from baseline method [9]. Gamma and beta distributions were applied to the cost and health
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utility parameters, respectively. Cost utility analysis was carried out and cost-effectiveness was
expressed as incremental cost per quality-adjusted life years gained, where appropriate. An
expected value of information analysis on the expected value of perfect information was also
carried out to quantify potential value of further research based on the difference between
expected net benefit with perfect information and existing information. For the model, it was
assumed that the life of the technology (the period over which the decision of whether gaba-
pentin compared with placebo, should be adopted remains relevant) is two years and the num-
ber of eligible participants has been estimated at 68,000 per annum in Scotland (based on a
prevalence of 38/1000 women) [3].
Results and Discussion
Recruitment and retention
From 137 eligible women, we randomized 47 (34%, 95% confidence interval 27%-43%) [Fig 1]
between 10 September 2012 and 30 September 2013 (follow-up of last participant in completed
31 March 2014). Twenty-two women were allocated to gabapentin, and 25 to placebo. We
were not able to capture all of the reasons why eligible women did not participate in the trial
but examples of reasons recorded included ‘already tried gabapentin’, ‘not wanting to take
daily pills’, and ‘symptoms improved since laparoscopy’. Baseline data were complete, and
baseline characteristics were evenly distributed between the randomized groups [Table 1 and
S1 Table].
25/47 (53%) had data available from the final follow up [Fig 1]. 37/47 (79%) took at least
two weeks of their medication [S2 Table]. The median number of weeks of medication taken
was six (interquartile range 2 to 9). The number of participants with follow up data was equally
distributed between the two treatment groups– 13 in the gabapentin group and 12 in the pla-
cebo group. One placebo participant who withdrew from treatment did have follow up data.
If women attempted to complete any follow up, then they generally did so fully, resulting in
very few missing data points amongst the forms that were collected. Amongst those that
answered at all, there were no missing data points for the VAS, PDQ, HADS and EQ5D. The
BPI was fully completed by 42 (89%) women at baseline, 25 (96% of those who answered) at
three months, and 21 (84% of those who answered) at six months. The WHO QOL was fully
completed by 47 (100%) women at baseline, 26 (100% of those who answered) at three months,
and 23 (92% of those who answered) at six months. In total, 20 (43%, 95% confidence interval
30%-57%) women fully completed all data collection forms and all of these took at least two
weeks of their medication.
Six participants took their prescribed medication for less than two weeks: three changed
their mind, one was withdrawn by the clinician due to a previous suicide attempt, and two
withdrew due to side effects (one on gabapentin, one on placebo). Of those participants that
took more than two weeks of treatment, ten withdrew. Three withdrew due to ‘lack of efficacy’
(one placebo, two gabapentin), two withdrew to try for a pregnancy, and five withdrew due to
side effects (three gabapentin, two placebo). Four out of ten women given gabapentin, and
seven out of ten women given placebo correctly guessed their treatment. This is similar to what
would be expected by random chance alone (50%).
Clinical efficacy
This was a feasibility study, and not large enough to produce reliable estimates of treatment
effects. However, outcome measures were compared between groups, to give an indication of
which measures might be likely to show a treatment effect in a larger study. Gabapentin was
statistically significantly better than placebo using the BPI pain scale and HADS anxiety scale
Gabapentin for Chronic Pelvic Pain in Women
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[Table 2]. Gabapentin was better than placebo, but with a wide confidence interval that could
include clinical significant benefit or harm, for the VAS, BPI interference scale and HADS
depression scale. Treatment effects were in opposite directions at three months and six months
for the psychosocial scale of the PDQ—favoring placebo at three months and gabapentin at six
months. However, these effects were not statistically significant. Gabapentin was worse than
placebo, but with a wide confidence interval that could include clinical significant benefit or
harm, for the function scale of the PDQ. There was no consistent pattern for the EQ-5D sub-
scales, and no statistically significant results [S3 Table]. The MYMOP was not analyzed as the
documentation of symptoms pre- and at the end of treatment was not accurately recorded by
participants in the trial.
Adverse events
17/22 (77%) gabapentin participants had an adverse event compared with 16/25 (64%) in the
placebo group [Table 3]. The majority of these events were mild (15 in each group). There
were two reported serious adverse events, both in the gabapentin group. However, both were
Fig 1. CONSORT flow chart for the GaPP1 trial.DNA = women who did not attend for screening.
doi:10.1371/journal.pone.0153037.g001
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exacerbations of CPP involving inpatient hospitalization that were not thought to be related to
gabapentin.
Acceptability to participants of proposed methods of recruitment/
randomisation/drug treatments/assessment tools
14 participants were interviewed for 10–15 minutes by an independent researcher before the
six-month appointment at which they were unblinded. The majority of participants described
their overall trial experience favorably, and rated it 1 or 2 on a 5-point scale from positive to
Table 1. Characteristics at randomisation–categorical.
Randomised treatment All
Gabapentin Placebo Participants
N % N % N %
Total number of participants randomised 22 100.0 25 100.0 47 100.0
Centre Edinburgh 14 63.6 16 64.0 30 63.8
Aberdeen 8 36.4 9 36.0 17 36.2
Deprivation category 1 1 4.5 1 4.0 2 4.3
2 2 9.1 4 16.0 6 12.8
3 5 22.7 6 24.0 11 23.4
4 6 27.3 4 16.0 10 21.3
5 5 22.7 4 16.0 9 19.1
6 2 9.1 5 20.0 7 14.9
7 0 0.0 1 4.0 1 2.1
NA 1 4.5 0 0.0 1 2.1
Ethnicity Caucasian 22 100.0 25 100.0 47 100.0
Parity None 14 63.6 17 68.0 31 66.0
1 or more 8 36.4 8 32.0 16 34.0
Contraception* Any used 21 95.5 23 92.0 44 93.6
Condoms 6 27.3 8 32.0 14 29.8
COCP 2 9.1 4 16.0 6 12.8
POP 1 4.5 1 4.0 2 4.3
Depoprovera 1 4.5 3 12.0 4 8.5
Nexplanon 2 9.1 0 0.0 2 4.3
Mirena 7 31.8 8 32.0 15 31.9
Copper IUD 0 0.0 0 0.0 0 0.0
Sterilised 1 4.5 0 0.0 1 2.1
Vasectomy 0 0.0 0 0.0 0 0.0
Contraceptive patch 0 0.0 0 0.0 0 0.0
Other 2 9.1 0 0.0 2 4.3
Marital Status Single 12 54.5 17 68.0 29 61.7
Separated 0 0.0 1 4.0 1 2.1
Married 4 18.2 2 8.0 6 12.8
Divorced 2 9.1 3 12.0 5 10.6
Living as married 4 18.2 2 8.0 6 12.8
Highest education received Secondary school 5 22.7 7 28.0 12 25.5
College/University 17 77.3 18 72.0 35 74.5
*Women could use more than one type of contraception.
doi:10.1371/journal.pone.0153037.t001
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Table 2. Exploratory analysis of outcome data.
Randomised treatment
Gabapentin Placebo
N mean sd N mean sd Diff in means 95% CI P
VAS Q3—How strong was the pain during the past 4 weeks on average?
Baseline 13 6.6 1.8 13 6.3 1.9
3m 13 4.2 2.7 13 5.1 2.3 1.13 -0.40 - +2.65 0.14
6m 13 3.6 2.4 12 4.5 2.3 0.98 -0.87 - +2.83 0.28
BPI pain
Baseline 13 4.9 2.1 13 3.9 2.3
3m 13 3.1 2.6 13 3.8 2.8 1.59 +0.03 - +3.14 0.05
6m 13 2.9 2.0 12 4.1 2.4 1.72 +0.07 - +3.36 0.04
BPI interference
Baseline 13 4.1 2.9 13 3.3 2.9
3m 13 3.1 2.5 13 3.2 2.7 0.57 -0.83 - +1.96 0.41
6m 13 3.2 2.9 12 3.1 1.9 0.00 -1.83 - +1.82 1.00
Pain Disability Questionnaire psychosocial
Baseline 13 26.7 15.0 13 27.2 13.5
3m 13 22.1 15.0 13 20.3 15.7 -2.27 -8.74 - +4.20 0.48
6m 13 16.2 14.8 12 20.2 16.1 2.34 -5.90 - +10.57 0.56
Pain Disability Questionnaire function
Baseline 13 37.5 17.8 13 35.5 17.5
3m 13 29.4 21.0 13 23.0 16.5 -5.25 -18.73 - +8.22 0.43
6m 13 23.9 25.3 12 20.3 14.8 -5.94 -20.93 - +9.05 0.42
Hospital Anxiety and Depression Scale—anxiety
Baseline 13 10.2 5.5 13 8.1 3.9
3m 13 8.1 5.4 13 8.2 4.2 1.98 -0.12 - +4.07 0.06
6m 13 7.5 5.7 12 9.8 5.3 4.35 +1.97 - +6.73 0.001
Hospital Anxiety and Depression Scale—depression
Baseline 13 6.7 3.6 13 4.9 3.6
3m 13 5.5 3.9 13 4.7 4.5 0.85 -1.41 - +3.10 0.45
6m 13 5.2 4.9 12 4.9 4.0 0.93 -1.81 - +3.66 0.49
The treatment effect is mean follow up (3m or 6m) value for placebo—gabapentin, adjusted for baseline values. Positive values indicate Gabapentin is
better than placebo. Baseline data are shown for those with 3m data.
doi:10.1371/journal.pone.0153037.t002
Table 3. Adverse events. Number of participants with at least one adverse event, and severity of the worst event per participant.
Randomised treatment All
Gabapentin Placebo Participants
N % N % N %
Total number of participants randomised 22 100.0 25 100.0 47 100.0
Had adverse event 17 77.3 16 64.0 33 70.2
Severity of worst event Mild 15 68.2 15 60.0 30 63.8
Moderate 0 0.0 1 4.0 1 2.1
Serious 2 9.1 0 0.0 2 4.3
doi:10.1371/journal.pone.0153037.t003
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negative. Positive responses were recorded for the recruitment approach used, paperwork bur-
den for participants and the experience of randomization of participants. A suggestion of using
electronic forms in a future trial was received favorably by participants. Negative feedback was
largely related to trial medication, diary completion and communication issues. Some women
experienced discomfort when swallowing large tablets; dose adjustment and managing side-
effects were also problematic as participants did not always know what dose they were on and
if symptoms were related to the drug or not. Some found the treatment diary too time consum-
ing to complete successfully although most managed it. Communication issues were few but
related to missed calls between participants and research nurses, and also a failure to read or
understand fully the trial literature.
Cost-effectiveness
The mean cost of gabapentin was £15.20 ($23) per participant, based on the assumption of
weekly dose escalation as described in the “dose regimen” section earlier. It was assumed that
no active treatment costs were incurred in the placebo arm. Costs associated with healthcare
resource use, including GP visits and GP telephone consultations were greater in the placebo
arm than the gabapentin arm [S4 Table]. As a result, the difference in mean total costs between
the two arms was small (£19/$28.7 in the gabapentin arm compared with £17/$25.7 in the pla-
cebo arm). Gabapentin was also associated with lower QALYs compared with the placebo arm;
however, the difference in QALYs is small [S4 Table]. Gabapentin is dominated by placebo.
Probabilistic sensitivity analysis based on 1000 simulations gave similar results, but showed
much uncertainty related to the parameter estimates [Fig 2]. The cost effectiveness acceptabil-
ity curve showed that at willingness-to-pay of £20,000 ($30,235) to £30,000 ($45,350), gaba-
pentin has a similar probability of being cost-effective than placebo at a probability of 51%
[Fig 3]. The expected value of perfect information analysis indicated that future research is
potentially cost-effective. At a willingness-to-pay threshold of £20,000, additional research is
Fig 2. Cost-effectiveness plane.
doi:10.1371/journal.pone.0153037.g002
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potentially cost effective if research is not proposed to exceed a cost of £325 million ($463
million).
Discussion
Our pilot trial supports the feasibility of a future large multicentre randomised controlled trial
to determine the efficacy of gabapentin in the management of CPP in women and provides pre-
liminary evidence that gabapentin could be effective.
Feasibility is supported by the fact that, over a one year recruitment period, we were able to
randomize 47 women (34% of those eligible) to gabapentin or matched placebo and obtain
completed six month follow up in 25 women (53%). Regarding effectiveness, analysis of one of
the pain scores (BPI questionnaire) used in the pilot indicates that participants randomized to
gabapentin perform better than placebo: 1.72 points, 95% CI: 0.07–3.36 at six months
(p = 0.04). In addition, analysis of the HADS anxiety scale used in the pilot supports an
improvement in mood: 4.35 points, 95% CI: 1.97–6.73 at six months (p = 0.001).
Analysis of the interview data regarding the delivery of the trial was generally favorable.
Most women were happy with the content, tone, and length of the written information
received, and the provision of verbal information was a valued addition. Negative feedback was
largely related to trial medication (large size of tablets), diary completion and communication
issues. Whilst the delivery of the medication cannot be altered, the other feedback has alerted
us to the need to develop the option of an online treatment diary and encourage better commu-
nication amongst the research staff (email, text) in the future trial.
Cost-effectiveness analysis showed that gabapentin and placebo has similar probabilities of
being cost-effective at they typical threshold for willingness to pay in the UK. However, this is
associated with high level of uncertainty; consequently, the value of future research to better
quantify the associated costs and clinical benefits is high.
Fig 3. Cost-effectiveness acceptability curve.
doi:10.1371/journal.pone.0153037.g003
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The level of recruitment in our pilot (34% of eligible women) was less than we had predicted
(50%). However, these data have allowed us to estimate recruitment more accurately in our
proposed future trial, and determine the number of centres (eight) and the recruitment period
that we will require (24 months). We have used information on efficacy to inform the power
calculation for the future trial (300 women).
A lower than expected proportion of patients followed up to six months (53%) has also
alerted us to the need to improve retention in our future trial. Thus, we will ensure that all
future trial centre research nurses understand that when a participant stops medication they
should be encouraged to provide follow-up data. We will monitor this very closely, and keep in
close contact with all trial centre staff. We will contact participants by other appropriate meth-
ods (email, telephone) to encourage replies. We plan to pioneer a database text message
reminder system for dose titration in the trial and for reporting of pain scores. We will engage
a commercial provider who can deliver reminder texts, e.g. for increasing the dose, and collect
responses to text messages requesting pain scores. Integration with the trial database will
enable automated texts to be sent according to a schedule determined by the consent and ran-
domization dates. We will provide an online facility for any participants wishing to complete
questionnaire booklets online. In addition, we will further analyze the current study to deter-
mine which factors predict ‘missingness’, so that we can plan appropriate missing data meth-
odology in the statistical analysis of the full study.
We are now ready to capitalize on our pilot study and have secured funding to perform a
definitive large multicentre double-blind randomised controlled trial to determine the true effi-
cacy of gabapentin in the management of women with CPP (EudraCT 2014-005035-13; for
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